Identifying economically justifiable pricing for key global markets

Our client’s ophthalmology product was at the end of its Phase 2 trial. The client recognised the importance of evaluating pricing possibilities and testing data ahead of a Phase 3 study. We were asked to conduct a comprehensive gap analysis to identify data that needed to be synthesised outside the Phase 3 study for a more informed pricing strategy.

To bridge the information gap, we carried out an SLR encompassing both clinical and economic perspectives. We sought informal clinician and payer advice on the company’s assumptions to ensure these were not only robust, but practical. Leveraging these insights, we developed a modelling approach in seeking early HTA advice. This not only helped validate assumptions but provided a structured framework for assessing potential outcomes and risks associated with pricing decisions.

With validated assumptions and a solid foundation from SLRs and stakeholder engagements, we proceeded to build a robust economic model utilising Phase 2 results and anticipated Phase 3 outcomes, allowing a more accurate prediction of the product’s value proposition

The comprehensive global economic model served as a key tool for reimbursement processes and evaluating the economic impact and market dynamics of the product. Armed with insights from the project, the client was able to establish an early and economically justifiable pricing strategy for key HTA markets.